Gsk Consumer Health, Inc.
Location
New Jersey
Founded
1994-02-28
Website
Risk Signals
9280 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Gsk Consumer Health, Inc.
Live alerts from global media, monitored by Business Radar
2025-07-08 (pharmabiz.com)
NPPA notifies separate retail price of GSK's cold medicine
The National Pharmaceutical Pricing Authority (NPPA) has notified the separate retail price of GlaxoSmithKline (GSK) Asia's cold medicine combination paracetamol 500 mg and phenylephrine HCl 10 mg at Rs. 6.96 per sachet, following an application by the company for separate pricing and the subsequent decision of the Multidisciplinary Committee (MDC) of experts.
Read more
2022-11-03 (huxiu.com)
GlaxoSmithKline has been suspended from centralized procurement: This is not the first time that drug quality problems are problem-
Something happened to GlaxoSmithKline again in the famous British pharmaceutical company. On October 31, the State Food and Drug Administration issued an announcement stating that after inspection, the State Food and Drug Administration found that GSK did not conduct batch-by-batch and full inspection of dutasteride soft capsules exported to China in accordance with the registration standards, and there were shortcomings in the prevention and control of microbial pollution risks. The State Food and Drug Administration decided to suspend the import, sale and use of this drug from now on. On the same day, the National Joint Procurement Office also made a statement: GSK's Dutasteride capsules are the fifth batch of national centralized procurement products...
Read more
2021-03-25 (fiercepharma.com)
FDA slaps Guillain-Barré warning on GlaxoSmithKline's star vaccine Shingrix |
GlaxoSmithKline's vaccine cash cow | GlaxoSmithKline's vaccine cash cow Shingrix has a new safety warning on its label after the FDA found an increased risk for the rare neuro autoimmune disorder Guillain-Barré Syndrome in a post-marketing study. But without establishing a causal link, the agency maintained the vaccine is safe.
Read more
2021-03-01 (pharmaceutical-technology.com)
EMA refuses asthma label expansion for GSK's COPD drug Trelegy Ellipta
The EMA has decided against a label expansion for GSK COPD drug Trelegy Ellipta to include asthma.
Read more
2020-05-28 (nutraingredients-usa.com)
NAD rules some Benefiber prebiotic supplements can't be called 'natural'
The National Advertising Division has ruled that GSK must stop calling some of its Benefiber prebiotic supplements '100% natural.' It's a ruling that could be viewed as troublesome for other prebiotic ingredients.
Read more